BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

478 related articles for article (PubMed ID: 33091561)

  • 1. A meta-analysis of reversion mutations in BRCA genes identifies signatures of DNA end-joining repair mechanisms driving therapy resistance.
    Tobalina L; Armenia J; Irving E; O'Connor MJ; Forment JV
    Ann Oncol; 2021 Jan; 32(1):103-112. PubMed ID: 33091561
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diverse
    Weigelt B; Comino-Méndez I; de Bruijn I; Tian L; Meisel JL; García-Murillas I; Fribbens C; Cutts R; Martelotto LG; Ng CKY; Lim RS; Selenica P; Piscuoglio S; Aghajanian C; Norton L; Murali R; Hyman DM; Borsu L; Arcila ME; Konner J; Reis-Filho JS; Greenberg RA; Robson ME; Turner NC
    Clin Cancer Res; 2017 Nov; 23(21):6708-6720. PubMed ID: 28765325
    [No Abstract]   [Full Text] [Related]  

  • 3. ALDH1A1 Contributes to PARP Inhibitor Resistance via Enhancing DNA Repair in BRCA2
    Liu L; Cai S; Han C; Banerjee A; Wu D; Cui T; Xie G; Zhang J; Zhang X; McLaughlin E; Yin M; Backes FJ; Chakravarti A; Zheng Y; Wang QE
    Mol Cancer Ther; 2020 Jan; 19(1):199-210. PubMed ID: 31534014
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BRCA1/2 reversion mutations in a pan-cancer cohort.
    Nakamura K; Hayashi H; Kawano R; Ishikawa M; Aimono E; Mizuno T; Kuroda H; Kojima Y; Niikura N; Kawanishi A; Takeshita K; Suzuki S; Ueno S; Okuwaki K; Sasaki J; Yamaguchi M; Masuda K; Chiyoda T; Yamagami W; Okada C; Nohara S; Tanishima S; Nishihara H
    Cancer Sci; 2024 Feb; 115(2):635-647. PubMed ID: 38041241
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer.
    Waks AG; Cohen O; Kochupurakkal B; Kim D; Dunn CE; Buendia Buendia J; Wander S; Helvie K; Lloyd MR; Marini L; Hughes ME; Freeman SS; Ivy SP; Geradts J; Isakoff S; LoRusso P; Adalsteinsson VA; Tolaney SM; Matulonis U; Krop IE; D'Andrea AD; Winer EP; Lin NU; Shapiro GI; Wagle N
    Ann Oncol; 2020 May; 31(5):590-598. PubMed ID: 32245699
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Lin KK; Harrell MI; Oza AM; Oaknin A; Ray-Coquard I; Tinker AV; Helman E; Radke MR; Say C; Vo LT; Mann E; Isaacson JD; Maloney L; O'Malley DM; Chambers SK; Kaufmann SH; Scott CL; Konecny GE; Coleman RL; Sun JX; Giordano H; Brenton JD; Harding TC; McNeish IA; Swisher EM
    Cancer Discov; 2019 Feb; 9(2):210-219. PubMed ID: 30425037
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An Effective Epigenetic-PARP Inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA Mutations.
    Pulliam N; Fang F; Ozes AR; Tang J; Adewuyi A; Keer H; Lyons J; Baylin SB; Matei D; Nakshatri H; Rassool FV; Miller KD; Nephew KP
    Clin Cancer Res; 2018 Jul; 24(13):3163-3175. PubMed ID: 29615458
    [No Abstract]   [Full Text] [Related]  

  • 8. Routine Plasma-Based Genotyping to Comprehensively Detect Germline, Somatic, and Reversion
    Vidula N; Rich TA; Sartor O; Yen J; Hardin A; Nance T; Lilly MB; Nezami MA; Patel SP; Carneiro BA; Fan AC; Brufsky AM; Parker BA; Bridges BB; Agarwal N; Maughan BL; Raymond VM; Fairclough SR; Lanman RB; Bardia A; Cristofanilli M
    Clin Cancer Res; 2020 Jun; 26(11):2546-2555. PubMed ID: 32034076
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of germline and somatic events in candidate BRCA-like genes on breast-tumor signatures.
    Bodily WR; Shirts BH; Walsh T; Gulsuner S; King MC; Parker A; Roosan M; Piccolo SR
    PLoS One; 2020; 15(9):e0239197. PubMed ID: 32997669
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polyclonal BRCA2 mutations following carboplatin treatment confer resistance to the PARP inhibitor rucaparib in a patient with mCRPC: a case report.
    Simmons AD; Nguyen M; Pintus E
    BMC Cancer; 2020 Mar; 20(1):215. PubMed ID: 32171277
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BRCA1/2 testing: therapeutic implications for breast cancer management.
    Tung NM; Garber JE
    Br J Cancer; 2018 Jul; 119(2):141-152. PubMed ID: 29867226
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Clinical Implications of Reversions in Patients with Advanced Pancreatic Cancer and Pathogenic Variants in BRCA1, BRCA2, or PALB2 after Progression on Rucaparib.
    Brown TJ; Yablonovitch A; Till JE; Yen J; Kiedrowski LA; Hood R; O'Hara MH; Teitelbaum U; Karasic TB; Schneider C; Carpenter EL; Nathanson K; Domchek SM; Reiss KA
    Clin Cancer Res; 2023 Dec; 29(24):5207-5216. PubMed ID: 37486343
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BRCA1/2 mutations and expression: response to platinum chemotherapy in patients with advanced stage epithelial ovarian cancer.
    Dann RB; DeLoia JA; Timms KM; Zorn KK; Potter J; Flake DD; Lanchbury JS; Krivak TC
    Gynecol Oncol; 2012 Jun; 125(3):677-82. PubMed ID: 22406760
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Darabi S; Braxton DR; Xiu J; Carneiro BA; Swensen J; Antonarakis ES; Liu SV; McKay RR; Spetzler D; El-Deiry WS; Demeure MJ
    Medicina (Kaunas); 2022 Dec; 58(12):. PubMed ID: 36557020
    [No Abstract]   [Full Text] [Related]  

  • 15. [Comparison of hereditary breast and ovarian cancer syndrome and sporadic ovarian cancer in ovarian cancer BRCA mutations].
    Duan RR; Sun LX; Zhao HW
    Zhonghua Fu Chan Ke Za Zhi; 2021 Nov; 56(11):788-795. PubMed ID: 34823292
    [No Abstract]   [Full Text] [Related]  

  • 16. The biological effects and clinical implications of BRCA mutations: where do we go from here?
    Stoppa-Lyonnet D
    Eur J Hum Genet; 2016 Sep; 24 Suppl 1(Suppl 1):S3-9. PubMed ID: 27514841
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PARP Inhibitors and Prostate Cancer: To Infinity and Beyond BRCA.
    Risdon EN; Chau CH; Price DK; Sartor O; Figg WD
    Oncologist; 2021 Jan; 26(1):e115-e129. PubMed ID: 32790034
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BRCA Methylation Testing Identifies a Subset of Ovarian Carcinomas without Germline Variants That Can Benefit from PARP Inhibitor.
    Sahnane N; Carnevali I; Formenti G; Casarin J; Facchi S; Bombelli R; Di Lauro E; Memoli D; Salvati A; Rizzo F; Sessa F; Tibiletti MG
    Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33352687
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of Circulating Cell-Free DNA Identifies Multiclonal Heterogeneity of
    Quigley D; Alumkal JJ; Wyatt AW; Kothari V; Foye A; Lloyd P; Aggarwal R; Kim W; Lu E; Schwartzman J; Beja K; Annala M; Das R; Diolaiti M; Pritchard C; Thomas G; Tomlins S; Knudsen K; Lord CJ; Ryan C; Youngren J; Beer TM; Ashworth A; Small EJ; Feng FY
    Cancer Discov; 2017 Sep; 7(9):999-1005. PubMed ID: 28450426
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Longitudinal profiling identifies co-occurring BRCA1/2 reversions, TP53BP1, RIF1 and PAXIP1 mutations in PARP inhibitor-resistant advanced breast cancer.
    Harvey-Jones E; Raghunandan M; Robbez-Masson L; Magraner-Pardo L; Alaguthurai T; Yablonovitch A; Yen J; Xiao H; Brough R; Frankum J; Song F; Yeung J; Savy T; Gulati A; Alexander J; Kemp H; Starling C; Konde A; Marlow R; Cheang M; Proszek P; Hubank M; Cai M; Trendell J; Lu R; Liccardo R; Ravindran N; Llop-Guevara A; Rodriguez O; Balmana J; Lukashchuk N; Dorschner M; Drusbosky L; Roxanis I; Serra V; Haider S; Pettitt SJ; Lord CJ; Tutt ANJ
    Ann Oncol; 2024 Apr; 35(4):364-380. PubMed ID: 38244928
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.